RESUMO
This study was conducted to compare serum Cytosolic beta-Glucosidase [CBG] levels of age-matched control patients with those of infants with neonatal necrotizing enterocolitis [NEC], to determine eventual association between Serum Cytosolic beta-Glucosidase levels with intensity of the disease in NEC infants. 82 neonates were divided into controls [group I, n=41], feeding intolerance [group II, n=15], and NEC [group III, n=26]. Serum Cytosolic beta-Glucosidase was measured at the onset of feeding intolerance or NEC and at weeks 2-3 in control infants [Group I] by ELISA. Data were analyzed using descriptive statistics, non-parametric tests and Student t-test. Median birth weights in three groups were 1761.3, 1951.9, 1893.7 g, median gestational ages were 33.6, 35.0 and 34.5 weeks and ages of sampling were 15.3, 14.7 and 15.1 days, respectively. The differences between NEC group, feeding intolerance group and the control group were not statistically significant [P>0.05]. There was a trend toward an increase in Serum CBG levels [group I 36.5 nmmol/L], group II [112.4 nmmol/L] vs. group III [693.0 nmmol/L], [chi[2]=43.296, P<0.01]. Infants in group III had highest CBG levels, compared with group II and I. Serum CBG is elevated in NEC, maybe NEC is the reason of high level of Serum CBG. In addition, the serum CBG may have utility as an early marker of ischemia in patients at risk for NEC in future studies
RESUMO
The aim of this study was to evaluate the efficiency and safety of ultrasound-guided thrombin injection on femoral pseudoaneurysm (FPA) as compared to ultrasound-guided local oppression. Eleven cases of FPA were enrolled and 7 cases received ultrasound-guide thrombin injection (injection group), and the remaining 4 cases were treated with local oppression (oppression group). Efficiency and safety were analyzed by ultrasound and subsequent follow-up. The results showed that 1 case relapsed in oppression group while no relapse occurred in thrombin injection group. Ultrasound-guided thrombin injection is better for treatment of FPA in terms of effectiveness and safety.